RT Journal Article
SR Electronic
T1 Inequalities in relative cancer survival by race, immigration status, income, and education for 22 cancer sites in Canada, a cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.05.31.24307976
DO 10.1101/2024.05.31.24307976
A1 Malagón, Talía
A1 Botting-Provost, Sarah
A1 Moore, Alissa
A1 El-Zein, Mariam
A1 Franco, Eduardo L.
YR 2024
UL http://medrxiv.org/content/early/2024/06/03/2024.05.31.24307976.abstract
AB Introduction There is a paucity of disaggregated data to monitor cancer health inequalities in Canada. We used data linkage to estimate site-specific cancer relative survival by race, immigration status, household income, and education level in Canada.Methods We pooled the Canadian Census Health and Environment Cohorts, which are linked datasets of 5.9 million respondents of the 2006 long-form census and 6.5 million respondents of the 2011 National Household Survey. Individual-level respondent data from these surveys were probabilistically linked with the Canadian Cancer Registry up to 2015 and with the Canadian Vital Statistics Database up to 2019. We used propensity score matching and Poisson models to calculate age-standardized relative survival by equity stratifiers for all cancers combined and for 22 individual cancer sites for the period 2006-2019.Results There were 757,485 primary cancer cases diagnosed over follow-up included in survival analyses; the age-standardized period relative survival was 72.5% at 5 years post-diagnosis. Relative survival was higher in immigrants (74.6%, 95%CI 74.3-74.8) than in Canadian-born persons (70.4%, 95%CI 70.2-70.6), and higher in racial groups with high proportions of immigrants. There was a marked social gradient by household income and education level, with 11-12% lower relative survival in cancer patients in the lowest household income and education levels than in the highest levels. Socioeconomic gradients were observed for most cancer sites, though the magnitude varied.Conclusions Despite the availability of universal healthcare in Canada, the observed differences in relative survival suggest there remain important inequities in cancer control and care.Competing Interest StatementSBP and AM have no conflicts of interest to declare. TM is a board member of the International Papillomavirus Society. ELF reports grants to his institution from the Canadian Institutes of Health Research, the National Institutes of Health, and Merck during the conduct of the study; and personal fees from Merck. MZ and ELF hold a patent related to the discovery "DNA methylation markers for early detection of cervical cancer", registered at the Office of Innovation and Partnerships, McGill University, Montréal, Québec, Canada.Funding StatementThis study was funded by a Canadian Institutes of Health Research (CIHR) (grant 179901) to E.L. Franco. The analysis presented in this paper was conducted at the Quebec Interuniversity Centre for Social Statistics (QICSS) which is part of the Canadian Research Data Centre Network (CRDCN); the services and activities provided by the QICSS are made possible by the financial or in-kind support of the Social Sciences and Humanities Research Council (SSHRC), the Canadian Institutes of Health Research (CIHR), the Canada Foundation for Innovation (CFI), Statistics Canada, the Fonds de recherche du Québec and the Québec universities.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of McGill University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesRestrictions apply to the availability of these data, which were used under license by Statistics Canada for this study. Eligible researchers can apply for data access through the Statistics Canada Research Data Centre program (https://www.statcan.gc.ca/en/microdata/data-centres/access). Program code and Poisson model outputs used for the current analyses are available at the Borealis repository at https://doi.org/10.5683/SP3/STER2V